Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Reuters
Apr 01
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

BRUSSELS, April 1 (Reuters) - A Belgian court on Wednesday ordered Poland and Romania to take delivery of 1.9 billion euros ($2.2 billion) worth of COVID-19 vaccines made by U.S. drugmaker Pfizer PFE.N.

Pfizer sued Poland and Romania in late 2023 in a Belgian court to force the two countries to comply with a contract signed between the European Commission and Pfizer for the delivery of a set number of vaccine doses over several years, the court said.

Poland refused in April 2022 to comply with the contract, citing the evolution of the pandemic, the war in Ukraine and a possible abuse of dominant position by Pfizer. Romania later took the same step.

The Brussels court rejected those arguments and ordered Poland and Romania to take delivery of the vaccine doses and pay Pfizer.

Poland was ordered to take delivery of Pfizer vaccine doses worth 1.3 billion euros, while Romania was ordered to take 600 million euros' worth.

Poland's health ministry had no immediate comment on the ruling. The Romanian government said it did not have an official announcement on the ruling and so could not comment.

($1 = 0.8614 euros)

(Reporting by Inti Landauro. Additional reporting by Alan Charlish and Luiza Ilie. Editing by Mark Potter)

((Inti.Landauro@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10